VolitionRx announced a 300% revenue increase in Q1 2026, reaching $1 million, driven by progress in their Capture-Seq™ cancer detection platform and Nu.Q® veterinary cancer tests. The company submitted a clinical manuscript for a feline lymphoma test, expecting a $5 million milestone payment, and is engaged in licensing talks with over a dozen global diagnostic firms. Their technology shows over 95% sensitivity for early-stage cancers and is expanding into sepsis detection with a finger-prick test. VolitionRx aims to secure licensing deals to commercialize their multi-billion dollar market opportunities, with routine clinical use in lung cancer expected in France by end of 2026.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
The producer price index (PPI) dropped by 0.3% in June following a slowdown in May, signaling easing inflation alongside a recent deflationary consumer price index (CPI) report. Real average hourly earnings rose 0.8% in June, marking the best wage ga...
President Donald Trump revealed that the US conducted another strike on Iran within 24 hours, aiming to dismantle the Iranian Revolutionary Guard Corps (IRGC), which he claims has lost about 90% of its weapons capabilities. Speaking at the Pennsylvan...
Ondo Finance announced the launch of the first tokenized equity representations using DTC tokenized entitlements, part of the DTCC Tokenization Service. This milestone pushed the ONDO token price up by about 5% and increased trading volume by 51.7% i...
